ArticleBMC pulmonary medicine2026
Impact of personalized biomedical risk assessment on smoking cessation counselling in chronic obstructive pulmonary disease.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmoking cessation reduces mortality and improves quality of life in chronic obstructive pulmonary disease (COPD). Brief physician counselling is effective for smoking cessation, but counselling is often not provided. We designed a personalized biomedical risk assessment infographic depicting predicted future lung function decline and corresponding clinical consequences occurring with versus without smoking cessation, to trigger and facilitate smoking cessation counselling at the point-of-care. Herein, we determined feasibility of its real-world implementation and impact on care.
methodsThis was a feasibility study of usual care (pre-intervention period) (year 1) followed by the infographic (intervention period) (year 2), at a tertiary care center (St. Michael's Hospital - SMH, University of Toronto). We recruited pulmonologists and primary care providers who refer patients to the SMH pulmonary function laboratory (PFL). Current smokers with COPD referred for spirometry by consenting providers were provided with the infographic through the PFL software, with instructions to bring this to their provider for discussion. Co-primary behavioural outcomes measured through e-chart review were: changes in the proportion of visits in which patients (1) received smoking cessation counseling; and (2) were prescribed/recommended smoking cessation pharmacotherapy.
resultsThere were 87 (median age 66.0 years; 60.0% male) and 104 (67.5 years; 63.0% male) eligible patients in the pre-intervention and intervention periods, respectively. Smoking cessation counselling was delivered in 58/86 (67.4%) versus 96/119 (80.7%) eligible visits (p = 0.045) and smoking cessation pharmacotherapy in 10/86 (11.6%) versus 22/119 (18.5%) visits (p = 0.25) in the pre-intervention period and intervention period, respectively. Changes in respiratory medications were more common in the intervention period (33.6%) compared to the pre-intervention period (22.6%) (p < 0.001). These changes were seen despite successful delivery of the infographic in only 60/119 (50.4%) eligible visits. Provider feedback was highly favorable.
conclusionsDespite an intervention fidelity of only 50%, our study suggests that a personalized biomedical risk assessment infographic increases smoking cessation counselling rates and may alter COPD management. Generation of the infographic should be automated to improve delivery, and the intervention should then be evaluated for its impact on smoking cessation.
trial registrationThe study was registered on October 7
Indexed as
Identifiers
42432647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.